<DOC>
	<DOCNO>NCT00259116</DOCNO>
	<brief_summary>This trial single center , open-label , dose-finding study recombinant human relaxin ( rhRlx ) give intravenously ( IV ) patient stable , compensated CHF .</brief_summary>
	<brief_title>A Pilot Study Recombinant Human Relaxin ( rhRlx ) Compensated Congestive Heart Failure</brief_title>
	<detailed_description>Serial cohort patient stable CHF enrol upon meeting eligibility criterion . Dose escalation guide hemodynamic response , safety tolerability . The effect rhRlx hemodynamics assess .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Methocarbamol</mesh_term>
	<criteria>Male female patient age 18 New York Heart Association ( NYHA ) Class IIIII CHF Left Ventricular Ejection Fraction ( LVEF ) &lt; 35 % Acute coronary syndrome Acute decompensated CHF Hypotension Recent significant arrhythmia Recent stroke Significant renal hepatic impairment Pregnancy childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Congestive heart failure</keyword>
	<keyword>Relaxin</keyword>
	<keyword>Cardiac hemodynamics</keyword>
</DOC>